ORIGINAL PAPERS

   BREAST CANCER

Proactive Management of Adverse Events Maintains the Clinical Benefit of Ixabepilone

Denise A. Yardley
The Oncologist 2009; 14: 448-455; doi:10.1634/theoncologist.2008-0284
[Abstract] [Full Text] [PDF]  

SUMMARY: This study reviews the safety profile of single-agent ixabepilone and combination ixabepilone plus capecitabine therapy, outlining the steps to effectively manage and prevent common adverse events.

Neuroendocrine Tumors of the Pancreas

Florian Ehehalt, Hans D. Saeger, C. Max Schmidt, Robert Grützmann
The Oncologist 2009; 14: 456-467; doi:10.1634/theoncologist.2008-0259
[Abstract] [Full Text] [PDF]  

SUMMARY: This literature review briefly summarizes the epidemiology, pathophysiology, clinical management, and outcomes of patients with pancreatic neuroendocrine tumors (PNETs) and highlights recent advances in PNET research.

The Impact of Consenter Characteristics and Experience on Patient Interest in Clinical Research

Drew W. Rasco, Yang Xie, Jingsheng Yan, Jennifer R. Sayne, Celette Sugg Skinner, Jonathan E. Dowell, David E. Gerber
The Oncologist 2009; 14: 468-475; doi:10.1634/theoncologist.2008-0268
[Abstract] [Full Text] [PDF]  

SUMMARY: This study evaluated the association between consenter characteristics and subject interest in clinical research and found that consenter experience and subject–consenter gender discordance were associated with greater subject interest in participating in future research.

Learning from Experience

Edward L. Trimble, Worta McCaskill-Stevens, Andrea Denicoff, Lucas Minig, Lori M. Minasian
The Oncologist 2009; 14: 476-477; doi:10.1634/theoncologist.2009-0073
[Full Text] [PDF]  

SUMMARY: This editorial praises the efforts of Rasco et al. to identify characteristics of consenters that affect patient recruitment to clinical trials.

Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer

Claus-Henning Köhne, Heinz-Josef Lenz
The Oncologist 2009; 14: 478-488; doi:10.1634/theoncologist.2008-0202
[Abstract] [Full Text] [PDF]  

SUMMARY: This overview of clinical studies describes the effects of administering the targeted agents bevacizumab, cetuximab, and panitumumab, also known as monoclonal antibodies, to treat metastatic colorectal cancer patients.

Managing Iron Overload in Patients with Myelodysplastic Syndromes with Oral Deferasirox Therapy

Elias Jabbour, Guillermo Garcia-Manero, Ali Taher, Hagop M. Kantarjian
The Oncologist 2009; 14: 489-496; doi:10.1634/theoncologist.2008-0154
[Abstract] [Full Text] [PDF]  

SUMMARY: This article discusses the knowledge and considerations of iron overload specific to myelodysplastic syndrome patients, as well as the clinical trial data that are currently available regarding chelation therapy with deferasirox, and provides recommendations for practical management approaches for patients with myelodysplastic syndrome.

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Francesco Grossi, Marianna Aita, Carlotta Defferrari, Francesco Rosetti, Annalisa Brianti, Gianpiero Fasola, Orazio Vinante, Paolo Pronzato, Giovanni Pappagallo
The Oncologist 2009; 14: 497-510; doi:10.1634/theoncologist.2008-0260
[Abstract] [Full Text] [PDF]  

SUMMARY: This study assessed the relative impact of third-generation drugs in first-line chemotherapy for advanced non-small cell lung cancer as measured by both response and progressive disease rates. The study found the agents to produce comparable response rates; however, paclitaxel-based third-generation regimens were associated with a significantly higher risk for immediate progression, whereas gemcitabine-containing regimens provided better disease control.

Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas

Angelo Delmonte, Michele Ghielmini, Cristiana Sessa
The Oncologist 2009; 14: 511-525; doi:10.1634/theoncologist.2008-0214
[Abstract] [Full Text] [PDF]  

SUMMARY: This review identifies and discusses new non–monoclonal antibody therapeutic agents in non-Hodgkin's lymphomas. The preclinical and clinical features of proteasome inhibitors, histone deacetylase inhibitors, thalidomide and lenalidomide, mammalian target of rapamycin inhibitors, antisense oligonucleotides, heat shock protein inhibitors, protein kinase C inhibitors, antiangiogenic agents, and new cytotoxics are reviewed.

Primary CNS Lymphoma in Immunocompetent Patients

Monica Sierra del Rio, Audrey Rousseau, Carole Soussain, Damien Ricard, Khê Hoang-Xuan
The Oncologist 2009; 14: 526-539; doi:10.1634/theoncologist.2008-0236
[Abstract] [Full Text] [PDF]  

SUMMARY: This review highlights the recent advances in the pathogenesis and treatment of primary central nervous system lymphoma in the immunocompetent population.

Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors

Tae Won Kim, Min-Hee Ryu, Heungnam Lee, Sun Jin Sym, Jae-Lyun Lee, Heung Moon Chang, Young Suk Park, Kyung Hee Lee, Won Ki Kang, Dong Bok Shin, Yung-Jue Bang, Jung Shin Lee, Yoon-Koo Kang
The Oncologist 2009; 14: 540-547; doi:10.1634/theoncologist.2008-0145
[Abstract] [Full Text] [PDF]  

SUMMARY: This study examines the influence of kinase mutational status on responses and outcomes to imatinib in patients with advanced gastrointestinal stromal tumors. Kinase mutational status, clinical responses to imatinib, and their relationship were evaluated in a cohort of consecutive Korean patients with metastatic or unresectable gastrointestinal stromal tumors.

High Incidence of Hypocalcemia and Serum Creatinine Increase in Patients with Bone Metastases Treated with Zoledronic Acid

Monica Zuradelli, Giovanna Masci, Giuseppe Biancofiore, Giuseppe Gullo, Marta Scorsetti, Pierina Navarria, Flavio Tancioni, Marco Berlusconi, Laura Giordano, Armando Santoro
The Oncologist 2009; 14: 548-556; doi:10.1634/theoncologist.2008-0227
[Abstract] [Full Text] [PDF]  

SUMMARY: This study aimed to establish the actual incidence of hypocalcemia and serum creatinine elevation during treatment with zoledronic acid. High incidences of these laboratory abnormalities were seen, strongly supporting the need for accurate monitoring of plasma calcium and creatinine levels during treatment.

New Era of Personalized Medicine: A 10-Year Anniversary

Jan Trøst Jørgensen
The Oncologist 2009; 14: 557-558; doi:10.1634/theoncologist.2009-0047
[Full Text] [PDF]  

SUMMARY: This letter comments on progress since the publication 10 years ago of the article by Langreth and Waldholz announcing a new era in personalized medicine.

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.